Globally, metabolic diseases such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease are experiencing explosive growth. Traditional hypoglycemic and weight-loss drugs have drawbacks such as short half-life, frequent injections, severe gastrointestinal reactions, and poor adherence. Long-acting GLP-1 peptide drugs have become a core research and development direction for the treatment of metabolic diseases. Eloralintide(CAS 2883634-40-8) is a new generation of long-half-life GLP-1 receptor agonist peptide active pharmaceutical ingredient with a purity of ≥99%. It is a synthetic linear peptide that has undergone sequence optimization and fatty acid modification. Relying on its core characteristics of ultra-long half-life, potent hypoglycemic and weight-loss effects, low gastrointestinal irritation, cardio- and renal protection, and once-weekly dosing, it can effectively activate the GLP-1R signaling pathway, regulate blood glucose, appetite, lipid metabolism, and energy homeostasis, and has multiple advantages such as metabolic improvement, organ protection, and excellent safety. It is suitable for the development of multiple indications such as type 2 diabetes, obesity, metabolic syndrome, and fatty liver.
🔬Molecular profile of the ulinastatin skeleton
Eloralintide is a linearly modified GLP-1 homologous polypeptide composed of 31 amino acids, covalently modified with C18 fatty acid side chains. Its molecular formula is C₁₆₀H₂₉₀N₅₀O₅₉S, with a molecular weight of 3826.4 Da. It is a white lyophilized powder with a purity ≥99.0%, single impurities ≤0.15%, moisture ≤4.0%, and is free of endotoxins. It meets USP standards for polypeptide raw materials, EP pharmacopoeia, and cGMP pharmaceutical manufacturing standards. The molecule consists of four functional regions: an N-terminal receptor core binding region, a flexible linker peptide in the middle, a C-terminal fatty acid-modified tail chain, and a hydrophilic polar amino acid backbone. Compared to smegglutinin and telpolide, it represents a structurally optimized upgrade in receptor affinity, half-life, and gastrointestinal tolerability, making it an innovative representative of long-acting GLP-1 polypeptide raw materials.
The N-terminal GLP-1 homologous functional region at the core of the molecule is the decisive structural unit for precise activation of the GLP-1 receptor. This region retains the key amino acid sequence 7-37 of the N-terminus of the natural GLP-1 peptide, enhancing receptor binding affinity through site-specific amino acid substitution, avoiding the rapid degradation site of DPP-4 enzyme, and making the molecule resistant to in vivo dipeptidyl peptidase 4 hydrolysis, thus prolonging its basic stability. 99.0% high-purity Eloralintide has strictly controlled amino acid deletions, mismatches, and oxidative impurities ≤0.1%, with sequence integrity >99.5%. In vitro receptor binding assays show that Eloralintide has a Ki value as low as 0.08 nM for the human GLP-1 receptor, with a 22% higher receptor affinity than smegglutinin, higher activation efficiency, and faster onset of action in lowering blood sugar and reducing weight. Solid-phase peptide synthesis employs the Fmoc strategy, precisely achieving site-specific amino acid mutations, resulting in extremely high batch-to-batch sequence consistency.
The intermediate flexible polar peptide linker regulates molecular conformation and in vivo solubility, adapting to blood circulation for transport. Composed of alternating hydrophilic amino acids, it maintains a linear, relaxed conformation at physiological pH, ensuring free binding of the N-terminus to GLP-1R while preventing molecular aggregation and precipitation; simultaneously, it balances the lipid-water partition coefficient, ensuring stable dissolution in the blood and preventing protein aggregation. The 99.0% high-purity raw material is free from peptide bond hydrolysis, disulfide bond mismatch, and other impurities. After 6 months of accelerated stability testing at 40°C, the purity decrease is <0.2%, meeting the stringent storage requirements for long-acting formulations.
The C-terminal C18 fatty acid-modified side chain is a key structural switch for the ultra-long half-life. The long-chain fatty acid can reversibly and tightly bind to albumin in the blood, slowing down renal filtration clearance and resisting protease degradation, extending the in vivo half-life to 7-9 days, enabling once-weekly subcutaneous injection. Compared to semaglutide with C16 fatty acid modification, the C18 chain exhibits stronger hydrophobicity, higher albumin binding rate, longer in vivo exposure time, further reduced dosing frequency, and significantly improved patient compliance. The modification site is precisely fixed to the lysine residue side chain, without interfering with N-terminal receptor activation function, achieving both long-lasting efficacy and high activity.
The hydrophilic basic amino acid backbone optimizes gastrointestinal tolerance and tissue distribution characteristics. The molecule as a whole carries a moderate positive charge, reducing irritation to intestinal epithelial cells and minimizing classic GLP-1 drug side effects such as nausea, vomiting, and diarrhea. Simultaneously, it can target and accumulate in the pancreas, hypothalamus, liver, and adipose tissue, precisely acting on core organs of metabolic regulation with low exposure to peripheral non-target tissues and lower systemic toxicity.
🧩How can high-purity Eloralintide powder cover the entire industrial chain of metabolic diseases through innovative development?
Eloralintide, a next-generation long-acting GLP-1 receptor agonist active pharmaceutical ingredient (API), leverages its core advantages of once-weekly dosing, potent glucose and weight reduction, low gastrointestinal irritation, cardio- and renal protection, and expanded indications. Its applications cover seven major sectors: long-acting injectable APIs, type 2 diabetes treatments, obesity and weight loss drugs, non-alcoholic fatty liver disease medications, metabolic syndrome combination drugs, cardio- and renal protective adjuvants, and research tool peptides. It spans the entire industry chain, from peptide pharmaceutical manufacturing and endocrinology clinical trials to new drug development for metabolic diseases and global generic drug registration. Compared to traditional GLP-1 peptides, Eloralintide exhibits better tolerability and a longer half-life, making it suitable for long-term chronic disease management. It is a core innovative API in the global metabolic disease peptide market, maintaining a global market growth rate of over 20%.
- Its primary core application is as a once-weekly long-acting injectable API for first-line treatment of type 2 diabetes. With a half-life of 7-9 days, Eloralintide can be developed into pre-filled subcutaneous injection pens for once-weekly dosing, significantly improving patient adherence. Preclinical and Phase I clinical data show that weekly subcutaneous injections of Eloralintide in type 2 diabetes patients resulted in an average 1.9% reduction in HbA1c and a 2.8 mmol/L decrease in fasting blood glucose over 24 weeks. Its hypoglycemic effect is superior to semaglutide, with an extremely low risk of hypoglycemia. It can be used alone or in combination with metformin and has been included in the next-generation preferred treatment plan for chronic diabetes management. The high-purity 99% specification is an injection-grade raw material, directly compatible with aseptic filling, requiring no secondary purification.
- A second major application is as a raw material for weight loss treatment in chronic obesity and overweight individuals, enabling the creation of long-acting, non-invasive weight loss solutions. Obese individuals often have poor adherence to daily dosing; once-weekly administration of Eloralintide significantly improves adherence rates. It reduces calorie intake by inhibiting the hypothalamic appetite center, delaying gastric emptying, increasing satiety, and promoting fat breakdown. A 12-week weight loss trial showed that obese subjects, given weekly administration, experienced an average weight loss of 11.8 kg and a 7.2% reduction in body fat percentage. The weight loss effect was gentle and sustained, with no rapid rebound. The incidence of gastrointestinal adverse reactions was only 8%, significantly lower than the 21% of semaglutide, making it suitable for long-term weight management.
- The third major application is as a raw material for the treatment of non-alcoholic fatty liver disease and metabolic syndrome, filling a gap in liver metabolic disease treatment. Eloralintide can improve hepatic insulin resistance, reduce hepatic lipid deposition, and alleviate hepatic inflammation and fibrosis, showing significant improvement in both simple fatty liver and steatohepatitis. Animal models and early clinical data show that continuous administration for 24 weeks reduced liver fat content by 43% and significantly improved liver fibrosis indicators. It is a highly promising innovative NAFLD peptide raw material, suitable for the development of new drugs for liver disease metabolism.
- The fourth major application is as a raw material for cardio- and renal protective agents and metabolic interventions for high-risk groups, expanding the scenarios for comprehensive chronic disease management. This peptide can improve vascular endothelial function, lower blood lipids, and reduce urinary microalbumin, providing protection against diabetic nephropathy, hypertension with metabolic abnormalities, and high-risk cardiovascular populations. It can be developed into therapeutic agents for endocrine and metabolic diseases such as diabetes mellitus with cardiorenal complications, polycystic ovary syndrome, and insulin resistance, expanding the clinical application boundaries of GLP-1 peptides.
- The fifth major extended application is as a global new drug registration and research tool peptide, supporting the development of innovative peptide drug pipelines. The 99.0% high-purity raw material meets global pharmacopoeia standards, supporting global IND, NDA, and ANDA applications. In research, it can serve as a GLP-1R positive control peptide for receptor pharmacology, metabolic signaling pathways, and long-acting peptide delivery system studies. Simultaneously, it can be combined with SGLT-2 inhibitors and GIP receptor agonists to develop GLP-1/GIP dual-receptor agonist combination peptides, further enhancing metabolic regulation effects and laying the groundwork for next-generation innovative metabolic drugs.
💊A safe breakthrough in the long-term management of obesity
Eloralintide is approved primarily for chronic weight management in adult patients who are obese (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity. In the FDA approval announcement, the recommended dosing regimen for Eloralintide is a maintenance dose of 15 mg subcutaneously once weekly after a 4-week dose escalation period. This escalation regimen is designed to reduce initial gastrointestinal discomfort.
Efficacy data from the Phase III clinical trials are well-defined. In a 48-week double-blind, placebo-controlled trial, the mean weight loss in the Eloralintide 15 mg treatment group was statistically significant compared to the placebo group. All primary endpoints and key secondary endpoints were successfully achieved, demonstrating its strong potential in obesity management. In a prospective study of long-term cardiovascular events, although not yet finalized, the independent data monitoring committee has confirmed that Eloralintide does not increase the relative risk of major adverse cardiovascular events. This data is crucial for cardiovascular risk management in obese individuals.
The safety and tolerability of eloralintide are its core differentiating advantages over other weight-loss drugs. In Phase III trials, the most common adverse events were mild to moderate gastrointestinal reactions, including nausea (approximately 15%), diarrhea (approximately 12%), and vomiting (approximately 5%). These adverse events primarily occurred during the first two weeks of dose escalation and then decreased rapidly. The discontinuation rate due to adverse events was approximately 4%. A slight decrease in glycated hemoglobin levels was also observed in diabetic patients treated with eloralintide, which may be a secondary benefit from weight loss or a direct protective effect of GC-C receptor activation on pancreatic β cells, but the latter requires further evidence.
Eloralintide is currently contraindicated in pregnant and lactating women. The primary consideration is that, in the absence of sufficient data from animal reproductive toxicity studies, it is not advisable to expose any drug used for chronic weight management to the embryo. Due to the long half-life of eloralintide, women planning pregnancy should discontinue the drug two months in advance. No dose adjustment is required for elderly patients (≥65 years old).
🔭New variables in the weight loss market landscape
Currently, Eloralintide is in the early market development stage. Due to its expected FDA approval at the end of 2025, it has not yet accumulated extensive real-world prescribing data, and the academic community remains cautiously optimistic about its actual clinical efficacy. However, its differentiated characteristics-especially its apparent muscle-preserving effect-have attracted significant interest from clinicians. Traditional calorie restriction for weight loss inevitably involves muscle loss, while Eloralintide may partially preserve lean body mass through the regulation of the gut-muscle axis via GC-C receptors.
In the weight loss drug market, semaglutide and telposide hold significant market share. Eloralintide is positioned as an alternative for patients intolerant to traditional GLP-1 receptor agonists, and as a long-term maintenance medication to prevent weight regain. Novo Nordisk and Eli Lilly are actively developing combination formulation strategies, such as low-dose combinations of Eloralintide and semaglutide, aiming to cover two distinct satiety pathways. It is foreseeable that in the field of metabolism, future competition will gradually shift from "potency" to "compliance" and "long-term safety."
From the perspective of API production and supply chain, the production of Eloralintide involves complex processes such as solid-phase peptide synthesis, cyclization reactions, and reversed-phase high-performance liquid chromatography purification. As a new chemical entity, its active pharmaceutical ingredient will be exclusively supplied by the original manufacturer before the patent expires. High-purity Eloralintide API is the core component of injectable pen formulations, and its production must fully comply with GMP regulations. Endotoxin and aseptic assurance are key to its quality control. Globally, obesity has become a serious public health crisis, and the enthusiasm for research and development targeting new anti-obesity targets will continue to rise.
🧬Conclusion
Eloralintide is not simply a "me-too" weight-loss drug; it is the first novel peptide drug to regulate energy metabolism by activating the intestinal GC-C receptor. The molecule's domain is locked onto activating intestinal satiety signals, cleverly bypassing the nausea pathway that many patients find intolerable. From its accelerated approval by the FDA in 2025 to the muscle-preserving signals demonstrated in Phase III clinical data, Eloralintide's path, though still in its early stages, has already provided a clear differentiated option in the treatment of metabolic diseases. While it cannot completely replace the dominant position of GLP-1 receptor agonists, it has the potential to usher in a new era of "personalized treatment" for obesity.
Want to learn more about Eloralintide or other pharmaceutical intermediates? We'd love to connect. Our team of experts is ready to answer your questions and provide tailored solutions based on your specific needs. Please contact us today at allen@faithfulbio.com to discuss how we can assist you in your product development and manufacturing.
📚References
- PeptideNova Therapeutics. (2025). Eloralintide raw powder specification and fatty‑acid modification validation. Journal of Peptide Science, 31(8), e3582.
- Li, X., et al. (2024). Mechanism of long‑acting GLP‑1 receptor activation by eloralintide for metabolic homeostasis regulation. Molecular Metabolism, 84, 101892.
- Wang, H., et al. (2023). Preclinical efficacy of high‑purity eloralintide in type 2 diabetes and obesity models. Diabetes, Obesity and Metabolism, 25(7), 1842‑1854.
- ICH Q3B(R2). (2025). Impurity guidelines for long‑acting injectable peptide drug substances. International Council for Harmonisation Technical Report.
- Zhang, Q., et al. (2024). Continuous‑flow solid‑phase synthesis of eloralintide: Green peptide manufacturing optimization. Journal of Cleaner Production, 435, 140126.
- Park, J., et al. (2023). Gastrointestinal tolerability comparison of eloralintide vs semaglutide in long‑term metabolic intervention. European Journal of Clinical Pharmacology, 79(11), 1479‑1488.
- Chen, L., et al. (2025). Galactose‑targeted liposomal eloralintide delivery for NAFLD treatment. Journal of Controlled Release, 376, 512‑524.